Find uplifting stories about heroes, innovations, and solutions
15 results for "lecanemab"
A newly approved Alzheimer's treatment in Malaysia can slow disease progression by more than eight years, giving patients precious extra time with their independence and loved ones. Unlike previous treatments that only managed symptoms, lecanemab actually changes how the disease progresses.
After two decades of setbacks, scientists have achieved a major breakthrough with Lecanemab, the first fully approved treatment that actually slows Alzheimer's progression. Over 200 more potential treatments are now racing through clinical trials, bringing real hope to millions of families.
Over 90% of Alzheimer's patients in Japan continue treatment with Lecanemab without serious side effects, new research confirms. The breakthrough drug slows disease progression by targeting brain plaque buildup.
Researchers finally solved the mystery of how lecanemab, an approved Alzheimer's drug, actually works in the brain. The discovery could lead to safer treatments for the 55 million people living with dementia worldwide.
A groundbreaking treatment that actually delays Alzheimer's progression just got approved in Canada, offering real hope to families facing dementia. The challenge now is making sure patients can access it.
For the first time in history, new drugs can slow Alzheimer's progression by years, not months. Scientists say better diagnosis and funding could turn these promising treatments into a genuine cure.
A groundbreaking therapy just approved in Canada can slow Alzheimer's progression by 30%, keeping patients independent longer. For the first time, doctors can target the root cause of the disease instead of just managing symptoms.
Women's superior verbal memory helps their brains compensate for Alzheimer's damage longer than men's, but this advantage means they get diagnosed and treated years too late. New research shows women pass standard memory tests for nearly three years longer despite having the same brain pathology as men.
Scientists in Spain have developed a breakthrough compound that doesn't just slow Alzheimer's disease but actually reverses memory loss and cognitive decline in mice. The drug works differently than current treatments by targeting the root genetic causes instead of just clearing protein plaques.
Families carrying rare Alzheimer's genes are volunteering for groundbreaking research that's helped develop new treatments. Their network faces uncertainty as federal funding stalls.
People with mild cognitive decline saw their memory and thinking skills improve after nine months of personalized treatments targeting nutritional deficiencies, inflammation, and lifestyle factors. The approach treats the root causes behind brain decline rather than just managing symptoms.
While expensive new Alzheimer's drugs grab headlines, doctors reveal that existing affordable medications work twice as well but only half of patients receive them. Researchers are now combining different approaches that could finally stop the disease.
A biomedical engineer at Georgia Tech is testing whether ski goggle-style lights and sound can slow Alzheimer's progression, offering hope for millions without the serious side effects of current drugs. Nearly 700 patients are now enrolled in a promising Phase 3 clinical trial.
Researchers discovered an enzyme called IDOL that, when removed from brain neurons, dramatically reduced Alzheimer's plaques and improved brain resilience. The breakthrough could lead to treatments that not only clear damaging proteins but actually help protect the brain from decline.
Scientists in Japan engineered a supercharged vitamin K that's three times better at turning stem cells into new brain neurons. The breakthrough could eventually help millions fighting Alzheimer's and Parkinson's disease.